Compare EDSA & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDSA | MYO |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.6M | 44.8M |
| IPO Year | 2018 | 2017 |
| Metric | EDSA | MYO |
|---|---|---|
| Price | $5.37 | $1.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $7.67 |
| AVG Volume (30 Days) | 51.5K | ★ 447.9K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,000,000,000.00 |
| Revenue This Year | N/A | $9.10 |
| Revenue Next Year | N/A | $13.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 40814.79 |
| 52 Week Low | $0.72 | $0.61 |
| 52 Week High | $20.32 | $1.59 |
| Indicator | EDSA | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 69.99 |
| Support Level | $4.80 | $0.92 |
| Resistance Level | $6.58 | N/A |
| Average True Range (ATR) | 0.57 | 0.12 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 68.35 | 90.01 |
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.